Recent news updates for Evommune (NYSE: EVMN) center around the clinical progression of its core pipeline candidates, updates regarding its mid-stage Phase 2 trial milestones for chronic inflammatory indications, and quarterly financial reports tracking its research and development expenditure cash runway following its initial public offering.